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BACKGROUND: N-methyl-D-aspartate receptor antagonists, such as ketamine, have rapid antidepressant effects in
patients with treatment-resistant depression (TRD). We hypothesized that nitrous oxide, an inhalational general
anesthetic and N-methyl-D-aspartate receptor antagonist, may also be a rapidly acting treatment for TRD.
METHODS: In this blinded, placebo-controlled crossover trial, 20 patients with TRD were randomly assigned to
1-hour inhalation of 50% nitrous oxide/50% oxygen or 50% nitrogen/50% oxygen (placebo control). The primary
endpoint was the change on the 21-item Hamilton Depression Rating Scale (HDRS-21) 24 hours after treatment.
RESULTS: Mean duration of nitrous oxide treatment was 55.6 6 2.5 (SD) min at a median inspiratory concentration
of 44% (interquartile range, 37%–45%). In two patients, nitrous oxide treatment was brieﬂy interrupted, and the
treatment was discontinued in three patients. Depressive symptoms improved signiﬁcantly at 2 hours and 24 hours
after receiving nitrous oxide compared with placebo (mean HDRS-21 difference at 2 hours, 24.8 points, 95%
conﬁdence interval [CI], 21.8 to 27.8 points, p 5 .002; at 24 hours, 25.5 points, 95% CI, 22.5 to 28.5 points,
p , .001; comparison between nitrous oxide and placebo, p , .001). Four patients (20%) had treatment response
(reduction $50% on HDRS-21) and three patients (15%) had a full remission (HDRS-21 # 7 points) after nitrous
oxide compared with one patient (5%) and none after placebo (odds ratio for response, 4.0, 95% CI, .45–35.79; OR
for remission, 3.0, 95% CI, .31–28.8). No serious adverse events occurred; all adverse events were brief and of mild
to moderate severity.
CONCLUSIONS: This proof-of-concept trial demonstrated that nitrous oxide has rapid and marked antidepressant
effects in patients with TRD.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2014.11.016Treatment-resistant depression (TRD) is a severe form of major
depressive disorder (1). Patients with TRD often fail multiple
treatments with standard antidepressants and have an unfav-
orable long-term prognosis; one in three patients with major
depression (estimated prevalence in the United States is 10
million adults) is affected (2). Therapeutic options for TRD are
very limited.
There is a strong biological rationale supporting the poten-
tial therapeutic use of nitrous oxide in TRD. Although nitrous
oxide is known to modulate several central nervous system
targets (3–14), like ketamine, the primary target of nitrous
oxide appears to be the N-methyl-D-aspartate (NMDA) recep-
tor, where nitrous oxide acts as a noncompetitive inhibitor
(15–17). NMDA receptor signaling has been implicated in the
neurobiology of depression and is a key component of central
nervous system information processing (18–20). Consistent
with the relevance of NMDA receptor signaling in the patho-
physiology of major depression, NMDA receptor antagonists,
such as ketamine (a general, dissociative anesthetic), have
been shown to provide rapid and sustained antidepressant& 2015 Society of Biological Psychiatry. This is an open access art
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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SEE COMMENTARY AReffects at subanesthetic doses in TRD (21–27). Given the
similar mechanisms of action, we hypothesized that nitrous
oxide may also have rapid antidepressant effects in TRD. This
proof-of-concept trial assessed the immediate (2 hours) and
sustained (24 hours) antidepressant effects of nitrous oxide in
a population of well-characterized patients with TRD.
METHODS AND MATERIALS
Study Design and Oversight
This study was designed as a randomized, placebo-controlled
crossover pilot clinical trial testing the antidepressant effects
of nitrous oxide in 20 patients with TRD. In this study, patients
had two treatment sessions that were 1 week apart (nitrous
oxide or placebo). The sequential order of the sessions was
assigned by a random number generator. Other than the gas
mixture administered, the sessions were indistinguishable in
setting, setup, and monitoring.
We undertook several measures to ensure treatment blind-
ing. First, we completely separated personnel and location oficle under the CC BY-NC-ND license
ISSN: 0006-3223
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performing psychiatric evaluations. The two locations were
physically separated from each other, and no team member
was allowed to enter the other space while a study patient was
present. Second, records for the nitrous oxide and placebo
treatment administration were kept separate from the psychi-
atric assessment case report forms until completion of the
study. Third, all equipment used to provide treatments was
identical between nitrous oxide and placebo sessions. Lastly,
patients were blinded as to the nature of the inhaled gas at
each inhalation session; all patients were informed that they
would receive either nitrous oxide or an air mixture with a high
nitrogen component (placebo).
A data and safety monitoring board monitored the trial. The
study was approved by the Washington University in St. Louis
Institutional Review Board, and all patients provided written,
informed consent. The trial was registered at clinicaltrials.gov
(NCT02139540).
Patients
Patients were recruited from an existing database of patients
with TRD administered by the Washington University Depart-
ment of Psychiatry and from the “Volunteers for Health”
patient pool (individuals with various medical or psychiatric
conditions who volunteer to participate in clinical research)
within Washington University School of Medicine. Inclusion
criteria were 1) age 18–65 years; 2) meeting DSM-IV-TR
criteria for major depressive disorder without psychosis, as
determined using a structured clinical interview [Mini Interna-
tional Neuropsychiatric Interview (28)]; 3) a pretreatment score
.18 on the 21-item Hamilton Depression Rating Scale (HDRS-
21); and 4) meeting criteria for TRD, deﬁned as having had at
least two adequate dose-duration, antidepressant medication
failures in the current depressive episode and a lifetime failure
of at least three antidepressant medication trials. Exclusion
criteria were 1) a history of bipolar disorder, schizophrenia,
schizoaffective disorder, obsessive-compulsive disorder,
panic disorder, or documented Axis II diagnoses; 2) active or
recent substance abuse or dependence (“recent” deﬁned as
within the past 12 months; exception was made for nicotine
use disorder); 3) the presence of acute medical illness that
could interfere with study participation, including, but not
limited to, signiﬁcant pulmonary disease; 4) active suicidal
intention; 5) active psychosis; 6) previous administration of
NMDA receptor antagonists (e.g., ketamine); 7) ongoing treat-
ment with electroconvulsive therapy; 8) pregnancy or breast-
feeding in female patients; and 9) contraindications against the
use of nitrous oxide (e.g., pneumothorax, middle ear occlu-
sion, elevated intracranial pressure, chronic cobalamin or
folate deﬁciency treated with folic acid or vitamin B12). Patients
were instructed to continue their current standard of care
treatment for major depression and were required to maintain
a stable medication or psychotherapy regimen without
changes for 4 weeks before initiation of the study and to
continue on the same dosage throughout the study.
Treatment
Patients received either an admixture of up to a maximum of
50% nitrous oxide and 50% oxygen (“active treatment”) or 50%Biolognitrogen/50% oxygen (“placebo”) for 1 hour. The inspiratory
nitrous oxide concentration was titrated during the ﬁrst 10 min
until 50% was achieved. The 50% nitrous oxide concentration
was selected in this pilot trial based on clinical experience for
sedation in dentistry and obstetric analgesia, where 50%
nitrous oxide has been used for decades with an excellent
safety and effectiveness record. We decided to maintain an
equal oxygen concentration (50%) in the placebo treatment to
limit the variability between treatment and placebo. The gas mix
was administered via a standard anesthesia facemask through
tubing connected to an anesthesia machine. A small sample
connector line was inserted into the facemask allowing the
measurement of inhaled and exhaled gas concentrations. Total
gas ﬂow was 4–8 L/min. Patients were monitored during and
after the treatment according to the American Society of
Anesthesiologists standard, which includes continuous three-
lead electrocardiogram, pulse oximetry, noninvasive blood
pressure, and end-tidal carbon dioxide under the supervision
of an attending-level anesthesiologist. After the 1-hour treat-
ment session, patients were transferred to a recovery area and
monitored for 2 hours. A study team physician determined if the
patients met criteria for discharge before patients were allowed
to leave the treatment facility.
Outcomes
Outcomes were assessed at six time points for each patient
(three per session; two sessions): at baseline (pretreatment),
2 hours after treatment for each session, and 24 hours after
treatment for each session. A 1-week outcome assessment
was not formally planned but was available as part of the
baseline assessment for the second treatment session. The
primary study endpoint was the change in the HDRS-21 at 24
hours after treatment. Secondary endpoints included change on
the Quick Inventory of Depressive Symptomatology Self Report
(QIDS-SR) scale. The primary mood assessment was selected
to be administered at 24 hours to ensure that any acute
euphoric effects of nitrous oxide had dissipated by this time
(nitrous oxide euphoric effects typically cease shortly after
discontinuation of nitrous oxide administration). Psychiatric
safety endpoints were assessed via careful clinical observations
and questioning for dangerousness to self (suicidality) as well
as for emergence of psychosis (hallucinations, delusions,
disorganized thinking). Other safety endpoints included cardio-
vascular, respiratory, and central nervous system adverse
events determined by hemodynamic and respiratory monitor-
ing. The extent of nitrous oxide–induced inactivation of vitamin
B12 was determined by measurement of plasma total homo-
cysteine before and after treatment.
Statistical Analysis
The primary outcome (HDRS-21) was analyzed with a
repeated-measures mixed effects linear model using restricted
maximum likelihood estimation. To adjust for the observed
carryover effect, the model included a randomization group
term and a three-way interaction (treatment 3 time 3
randomization group). Also, we performed a similar repeated-
measures mixed model for only the ﬁrst treatment session
(with a two-way interaction). These analyses were repeated for
the QIDS-SR scale.ical Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journal 11
Table 1. Baseline Characteristics
Age, Years 48 (30–55)
Female Sex 12 (60%)
White Race 20 (100%)
Depression History, Years 19 (11–27)
Number of Failed Treatments 8 (4–12)
Baseline HDRS-21 Score 23.5 (22.3–25.0)
Baseline QIDS-SR Score 19 (15.3–20.8)
Vagus Nerve Stimulator 3 (15%)
History of ECT 4 (20%)
Number of Current Antidepressant Medications 2 (0–2)
History of Migraine 10 (50%)
History of Hypothyroidism 4 (20%)
Current Medication
Antidepressants 13 (65%)
SSRI 6 (30%)
SNRI 5 (25%)
Bupropion 5 (25%)
Clomipramine 1 (5%)
Atypical Antipsychotics
Quetiapine 2 (10%)
Aripiprazole 1 (10%)
Anticonvulsants
Lamotrigine 3 (15%)
Other
Benzodiazepine 2 (10%)
Atomoxetine 1 (5%)
Dextroamphetamine 1 (5%)
Methylphenidate 1 (5%)
Values are median and interquartile range or numbers and percen-
tages.
ECT, electroconvulsive therapy; HDRS-21, 21-item Hamilton
Depression Rating Scale; QIDS-SR, Quick Inventory of Depressive
Symptomatology Self Report; SSRI, selective serotonin reuptake
inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor.
Table 2. Adverse Outcomes
Adverse Event Nitrous Oxide Placebo
Nausea and Vomiting 3 (15%) 0
Headache 2 (10%) 2 (10%)
Dizziness/Lightheadedness 1 (5%) 2 (10%)
Numbness/Paresthesia 2 (10%) 0
Anxiety 2 (10%) 0
Panic Attack 1 (5%) 0
Hypercapnia 0 1 (5%)
Claustrophobia 1 (5%) 0
Hyperventilation 1 (5%) 0
Regurgitation 1 (5%) 0
Values are numbers and percentages.
Figure 1. Effects of nitrous oxide treatment on depressive symptoms
measured on the 21-item Hamilton Depression Rating Scale (HDRS-21). (A)
Absolute change on the HDRS-21. (B) Normalized response (adjusted for
baseline) on the HDRS-21. Patients were evaluated at three time points:
baseline (pretreatment), 2 hours after treatment completion, and 24 hours
after treatment completion. Nitrous oxide provided a signiﬁcantly more
pronounced reduction in depressive symptoms compared with placebo
(p , .001). Data are presented as mean 6 95% conﬁdence interval. Blue
circles, nitrous oxide (N2O); squares, control (placebo); **p , .01; ***p , .001.
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between the two treatments (using the paired data structure),
an exact binomial test was used (and corresponding odds
ratios [ORs] calculated) because the number of discordant pairs
was ,20. Data are presented as mean 6 SD or 95%
conﬁdence intervals [CIs] or as median and interquartile range.
Because this was the ﬁrst in-human patient pilot study, no
prior knowledge existed for adequate sample size determina-
tion. We based our sample size (20 patients with TRD) on
available results from ketamine trials in similar populations,
where a signiﬁcant antidepressant effect was observed in ,20
patients. JMP Pro 11.1 and SAS 9.3 (SAS Institute, Inc, Cary,
North Carolina) and GraphPad Prism 6.04 (GraphPad Soft-
ware, Inc, La Jolla, California) were used for the statistical
analysis and graphing. All reported p values are two-sided,
and a p value , .05 was considered statistically signiﬁcant.
RESULTS
Patients
Between November 2012 and February 2014, we enrolled
24 patients with TRD into the trial. After excluding three12 Biological Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journapatients for screen failure, 21 patients were randomly
assigned to a study group (Figure S1 in Supplement 1).
One patient withdrew after the ﬁrst session and before any
outcomes could be assessed, leaving an evaluable patient
population of 20 patients who received both treatments andl
Nitrous Oxide and Treatment-Resistant Depression
Biological
Psychiatrycompleted the follow-up assessment. All results are
reported from these 20 evaluable patients (modiﬁed inten-
tion-to-treat).
Patients had on average 19 lifetime years of major depres-
sive disorder, failed a median of eight (adequate dose/dura-
tion) antidepressant drug treatments, and were taking a
median of two antidepressants at the time of study parti-
cipation (Table 1). The median HDRS-21 score at enrollment
was 23.5 (interquartile range, 22.3–25.0), and the median
QIDS-SR was 19 [interquartile range, 15.3–20.8], indicative of
severe depression.
Treatment
The full 60-min treatment with nitrous oxide was completed by
15 patients; the treatment was interrupted for 5 min in 2
patients and was discontinued (at 55, 28, and 18 min for
emotional discomfort, regurgitation, claustrophobia, or nausea
and vomiting [Table 2]) in 3 patients. The mean duration of
nitrous oxide treatment was 55.6 6 2.5 (SD) min at an average
inspiratory nitrous oxide concentration of 44% (37%–45%,Figure 2. Individual depressive symptoms from the 21-item Hamilton Depres
Depression Rating Scale that showed the largest change (depressed mood, gu
graphs in order of severity (red 5 severe, white 5 absent) between the six diffe
Biologmedian, interquartile range). All patients completed the full
60-min placebo treatment.
Study Outcomes
Patients experienced a signiﬁcant improvement in depres-
sive symptoms at 2 hours and 24 hours after receiving
nitrous oxide (mean difference in HDRS-21 score at 2 hours,
24.8 points, 95% CI, 21.8 to 27.8 points, p 5 .002; at 24
hours, 25.5 points, 95% CI, 22.5 to 28.5 points, p , .001)
compared with placebo (mean difference in HDRS-21 score
at 2 hours, 22.3 points, 95% CI, .8 to 25.3 points, p 5 .14;
at 24 hours, 22.8 points, 95% CI, .2 to 25.8 points, p 5 .07;
comparison between nitrous oxide and placebo, p , .001)
(Figure 1). Figure 2 shows the response within individual
symptoms from the HDRS-21 that showed the biggest
change: depressed mood, guilt, suicidal ideation, and
psychic anxiety. On the QIDS-SR scale, patients experi-
enced a signiﬁcant reduction at 24 hours after nitrous oxide
treatment (mean, 23.2 points, 95% CI, 21.3 to 25.0 points,
p 5 .001 between baseline and 24 hours) compared withsion Rating Scale. The four depressive symptoms on the 21-item Hamilton
ilt, suicidal ideation, and psychic anxiety) are depicted as color-coded bar
rent time points of the trial. BL, baseline; N2O, nitrous oxide.
ical Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journal 13
Table 3. Change in Level of Depression Severity 24 Hours
After Treatment
Nitrous Oxide Control
Worse ↑ 1 0 ↑ 1 1/20 (5%)
Neutral 0 6/20 (30%) 0 12/20 (60%)
Better ↓ 1 7/20 (35%) ↓ 1 5/20 (25%)
↓ 2 3/20 (15%) ↓ 2 1/20 (5%)
↓ 3 3/20 (15%) ↓ 3 1/20 (5%)
↓ 4 1/20 (5%) ↓ 4 0
Relative change after treatment according to the ﬁve levels of
depression severity on the 21-item Hamilton Depression Rating Scale
(normal, mild, moderate, severe, very severe). Downward arrows
indicate improvement; upward arrows indicate worsening of depres-
sive symptoms compared with baseline. For example, a two-level
improvement would be from severe depressive symptoms to mild.
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comparison nitrous oxide vs. placebo, p 5 .003) (Figure S2
in Supplement 1).
At 24 hours, four patients (20%) had treatment response
(deﬁned as reduction in depressive symptoms $50% on the
HDRS-21) after receiving nitrous oxide compared with one
patient (5%) after placebo treatment (OR, 4.0, 95% CI,
.45–35.79) (Figure 3A). Three patients (15%) had a full
remission after nitrous oxide treatment (deﬁned as complete
resolution of depressive symptoms, HDRS-21 # 7 points); no
patients had full remission after placebo (OR, 3.0, 95% CI,
.31–28.8) (Figure 3B).
Subdividing the HDRS-21 scale into ﬁve levels of depres-
sion severity (normal, mild, moderate, severe, very severe),
7 of 20 patients (35%) had at least a two-level improvement
24 hours after receiving nitrous oxide (i.e., from severe to mild)
compared with 2 patients receiving placebo (10%; p 5 .06)
(Table 3). Table S1 in Supplement 1 shows the response on
the QIDS-SR scale.Figure 3. Clinical outcomes after nitrous oxide and placebo treatment.
Rates of response (A) (deﬁned as a reduction in 21-item Hamilton
Depression Rating Scale score $50%) and remission (B) (deﬁned as
complete resolution of depressive symptoms, 21-item Hamilton Depression
Rating Scale score #7) 24 hours after treatment are shown. Compared with
placebo, nitrous oxide had a fourfold higher response (odds ratio, 4.0, 95%
conﬁdence interval, .45–35.79) and threefold higher remission rate (odds
ratio, 3.0, 95% conﬁdence interval, .31–28.8).
14 Biological Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journaFirst Treatment Session–Only Analysis
In this crossover trial, we expected depressive symptoms to
revert to baseline after 1 week when patients returned for their
second treatment session. However, several patients showed
markedly lower HDRS-21 scores after the 1-week interval,
indicating a signiﬁcant carryover effect (p 5 .02). The heat map
in Figure 4 shows a signiﬁcant difference between HDRS-21
scores of the 10 patients who received nitrous oxide ﬁrst and the
10 patients who received placebo (p5 .02 for difference between
randomization groups). To address this carryover effect, we
additionally analyzed the ﬁrst treatment session only (i.e., com-
pared the 10 patients who received nitrous oxide with 10 who
received placebo, akin to a parallel group design). This analysis
allowed us to include 1-week outcomes because it represents the
baseline assessment for the second treatment session.
Patients who received nitrous oxide ﬁrst (n 5 10) had a
signiﬁcant improvement of depressive symptoms at 2 hours,
24 hours, and 1 week (mean reduction of HDRS-21 at 2 hours,
27.1 points, 95% CI, 22.4 to 211.8 points; at 24 hours, 28.6
points, 95% CI, 24.4 to 212.8 points; at 1 week, 25.5 points,
95% CI, 2.8 to 210.2 points) compared with patients who
received placebo ﬁrst (n 5 10) (at 2 hours, 22.9 points, 95%
CI, 1.7 to 27.6 points; at 24 hours, 24.7 points, 95% CI,
2.0 to 29.4 points; at 1 week, 24.4 points, 95% CI, .3 to
29.1 points) (Figure 5).
Safety
No serious adverse events occurred. All adverse events
(Table 2) were temporary. No increase in plasma total homo-
cysteine was observed after nitrous oxide or placebo treat-
ment, indicating minimal inactivation of vitamin B12–dependent
metabolism by nitrous oxide (Figure S3 in Supplement 1).DISCUSSION
This proof-of-concept trial demonstrated that nitrous oxide
has rapid antidepressant effects in patients with TRD. These
antidepressant effects were sustained for at least 24 hours
and in some patients for 1 week. Nitrous oxide resulted in a
treatment response in 20% of patients with TRD and remission
in 15%. Although a subset of patients experienced adverse
events requiring a short interruption or discontinuation of
treatment, the mild to moderate nature and immediatel
Figure 4. Cell plot (heat map) of individual responses of ﬁrst treatment session. Nitrous oxide (n 5 10) on the left and placebo (n 5 10) on the right,
measured on the Hamilton Depression Rating Scale colored to indicate severity of symptoms (red 5 severe, blue 5 less severe). Each row represents an
individual patient. Patients in the left plot are different from the ones in the right plot. HDRS, Hamilton Depression Rating Scale.
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gest an acceptable risk/beneﬁt ratio for nitrous oxide use in
the setting of TRD.
The internal validity of our crossover trial was affected by
the observed carryover effect (i.e., patients having a different
baseline at different treatment sessions). In our study, several
patients who returned for their second treatment session had
markedly lower depression scores. Typically, carryover effects
bias results toward the null hypothesis (i.e., reduce the
observable effect size) (29,30). This was the case in our study:
the 10 patients who received nitrous oxide treatment ﬁrst had
a mean reduction in depressive symptoms of 8.6 points on the
HDRS-21 compared with 5.5 points for the full cohort. This
observation supports the notion that nitrous oxide has true
antidepressant efﬁcacy. A second effect that inﬂuenced the
internal validity of our trial was the presence of a placebo
effect. Placebo effects are common in trials of antidepressants
(22,31,32) and may introduce bias by masking or exaggerating
treatment effects.
Pilot studies, such as this early phase II clinical trial, are
designed to detect an efﬁcacy signal in a small group of
patients and cannot provide robust and deﬁnitive measures of
effectiveness. Pilot trials should be interpreted with caution
because results must be replicated in larger cohorts. Although
the antidepressant efﬁcacy results in this trial are promising,
several potential limitations should be taken into considera-
tion. First, although our study team went to great lengths to
maintain blinding, the euphoric effects of nitrous oxide inha-
lation are difﬁcult to mask. Nitrous oxide induces sedation and
has a slightly sweet smell and taste. It is possible that someBiologpatients were able to determine whether they were receiving
nitrous oxide or placebo inhalation. We did not test patients to
determine if they were aware of their group assignment, and
this limits our conclusions. We intentionally selected the 24-
hour postinhalation mark as the primary measure to minimize
acute euphoric effects. However, there remains the possibility
that nitrous oxide inhalation may have produced a “masking”
of depressive symptoms (i.e., the depressive symptoms were
not really altered, but rather “covered up” by other effects).
Symptom “masking” has been observed with rapidly acting
psychostimulants (methylphenidate and cocaine), which pro-
mote a transient alteration in mood but not a true antidepres-
sant effect (33,34).
Second, although we clinically assessed the presence of
euphoria and psychosis at each time point, we did not do
standardized testing of either. In general, at 2 hours and 24
hours, the patients did not report euphoric feelings. Third, the
use of the HDRS-21 and QIDS-SR scales to measure rapid
antidepressant action was a limitation because both scales
assess symptom changes occurring over the course of days
and weeks rather than hours, including questions related to
sleep and weight, and are not ideal for assessing changes in
antidepressant action that occur rapidly. Different scales, such
as the International Positive and Negative Affect Schedule
Short Form or a visual analog scale, might have been superior.
Fourth, we had no prior knowledge about dosing in this patient
population and opted to use a 50% inspiratory concentration
of nitrous oxide, a dose commonly used in dentistry and
obstetric analgesia. Subsequent studies may determine that
different dosing regimens improve efﬁcacy and tolerance.ical Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journal 15
Figure 5. Effects of nitrous oxide treatment on depressive symptoms for
only the ﬁrst treatment session (10 patients each) measured on the 21-item
Hamilton Depression Rating Scale (HDRS-21). Absolute (A) and relative (B)
changes on the HDRS-21 compared with baseline (pretreatment) and
2 hours, 24 hours, and 1 week after treatment. Nitrous oxide provides a
signiﬁcantly stronger reduction in depressive symptoms compared with
placebo. The HDRS-21 scores at 1 week were derived when patients
returned for their second session (baseline HDRS-21 score for session 2).
The HDRS-21 scores 1 week after nitrous oxide treatment are signiﬁcantly
lower than at baseline, indicative of a sustained treatment effect. N2O,
nitrous oxide.
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gated NMDA receptor antagonist drug in major depressive
disorder, nitrous oxide had a similarly rapid onset of anti-
depressant action (within 2 hours) but appeared to be devoid
of psychotomimetic side effects seen with ketamine (delu-
sions, illusions, hallucinations), which may result from the
more favorable pharmacokinetics of nitrous oxide because its
offset occurs on the order of minutes (22,27,35–37). The fact
that both ketamine and nitrous oxide have antidepressant
effects in patients with TRD supports the notion that NMDA
receptor signaling plays a crucial role in the neurobiology of
major depressive disorder (18–21,38,39). However, recent
data indicate that other neurotransmitter receptor systems,
including nicotinic acetylcholine receptors, may be important
contributors to rapid antidepressant actions (40,41).
We can only speculate why certain NMDA receptor antag-
onists (ketamine, nitrous oxide) appear to have rapid antide-
pressant properties, whereas others, such as memantine, do16 Biological Psychiatry July 1, 2015; 78:10–18 www.sobp.org/journanot. Differences in NMDA receptor channel blocking seem
unlikely to contribute because differences between ketamine
and memantine are often observable only under extreme
depolarization or pathologic receptor activation (simulated
ischemia) (42). The presence of extracellular magnesium may
distinguish the effects of ketamine and memantine on NMDA
receptors, with memantine being relatively ineffective against
NMDA receptor–mediated synaptic currents in magnesium (43).
This latter effect also appears to contribute to differences in the
ability of the two drugs to promote brain-derived neurotrophic
factor production. Differences in mode of administration and
pharmacokinetics may also contribute to observed clinical
differences between ketamine and memantine. Although nitrous
oxide, similar to ketamine, is a noncompetitive NMDA receptor
antagonist, it differs from ketamine in lacking use dependence
and is not a trapping open channel blocker (15). Nitrous oxide
represents an alternative way to modulate NMDA receptor
function clinically.
Although a single administration of 50% nitrous oxide/
oxygen has been found to be generally safe (4% nonserious
adverse event rate among 25,828 patients receiving sedation
(44)), two potential safety concerns exist. First, nitrous oxide
administration had to be interrupted or discontinued in a
subset of our patients (typically near the end of the 1-hour
treatment session), and the adverse event proﬁle indicates that
some patients may experience emotional discomfort, para-
doxically increased anxiety levels, and nausea during nitrous
oxide administration. Although nearly all side effects were
limited to the immediate treatment period and disappeared
shortly after discontinuation, their nature suggests that per-
haps a shorter treatment duration or lower nitrous oxide
concentration may be advantageous.
A second potential safety concern relates to inactivation of
vitamin B12 by nitrous oxide (45,46). Although a single
exposure is unlikely to result in clinically relevant hematologic
or neurologic complications (47,48), the risk for such compli-
cations is substantially higher when nitrous oxide administra-
tions are repeated within short periods of time (5).
Hematologic and neurologic complications, such as megalo-
blastic anemia and myelopathy, have been reported among
persons who chronically abuse nitrous oxide (49) and patients
with chronic disturbances of folate metabolism (50,51). It is
likely that for sustained antidepressant effect, nitrous oxide
must be administered several times, which would increase the
risk for such complications. Nitrous oxide is a drug of abuse,
and its abuse potential represents a potential limitation for its
clinical utility in major depressive disorder. Our pilot study was
not designed to address this safety concern.
In conclusion, this preliminary, proof-of-concept clinical trial
provides the ﬁrst evidence that nitrous oxide may have rapid
and marked antidepressant effects in patients with TRD.
Subsequent studies are required to determine optimal anti-
depressant dosing strategies and the risk/beneﬁt ratio of
nitrous oxide in a larger and more diverse population of
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